Latest Strategy Changes News

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Arika Resources has reported significant extensions to gold mineralisation at its Yundamindra Gold Project in WA, alongside a successful $5.7 million capital raising and strategic asset sale.

Boab Metals has locked in over A$350 million in funding and made a Final Investment Decision to develop its Sorby Hills Silver-Lead-Zinc Project, moving swiftly towards first production in the second half of 2027.

Toubani Resources has landed a credit-approved term sheet from Coris Bank for more than US$80 million in project financing, marking a significant step forward for its Kobada Gold Project in Mali.

dorsaVi has launched a multi-year collaboration with leading Asian research institutes to develop its proprietary RRAM technology at the 22-nanometer node, targeting AI-driven robotics and wearable applications.

Future Metals NL has outlined strategic initiatives to enhance its flagship Panton PGM Project, leveraging rising platinum group metal prices and new processing opportunities. Key work programs and management appointments position the company for accelerated development in 2026.

Aurelia Metals announces Managing Director Bryan Quinn will resign by July 2026, with a leadership search underway amid key project developments.

Element 25 Limited has made significant strides in advancing its Butcherbird Expansion Project in Western Australia, securing $60 million in funding and progressing key engineering and contract milestones. Simultaneously, the company moves closer to finalising financing for its US-based battery-grade manganese refinery.

American Uranium Limited has reported significant progress at its Lo Herma ISR uranium project, completing extensive drilling and validating aquifer conditions that support in-situ recovery mining. The company is poised to update its resource estimates and advance development plans in 2026.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Meteoric Resources has cleared a major regulatory hurdle with the approval of its Preliminary Environmental License for the Caldeira Rare Earths Project, enabling the company to progress towards construction and first production targeted for 2028. The company also commissioned its pilot plant, producing its first batches of rare earth carbonate.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.